Skip to main content
Main Menu
Utility Menu
Search
HARVARD.EDU
GA4 tracking code
Subscribe
Donate
Contact Us
Search
About
Leadership
Faculty
Annual Reports
Contact Us
Research
Disease Programs
Aging & Fibrosis
Stem Cells as Tools
Early-Stage Research
For Patients
Training
Internship Program
MD/PhD Fellowship
Startups
Commercialization
Community
Events
Funding Opportunities
Centers & Cores
Job Opportunities
News
Newsletter Archive
HOME
/
Kevin Eggan, HSCI Principal Faculty
Download original image
« Back to gallery
Item 18 of 39
« Previous
|
Next »
“As is often the case, I had a lot of great 40,00-foot view conversations with Doug Melton. When we worked next door to one another, he would wander into my lab and say things like, ‘why don’t we make disease specific stem cell lines?’” Eggan and his colleagues created the first patient-specific cell lines, which they generated from adult patients with the genetic muscle-wasting disease amyotrophic lateral sclerosis (ALS). In a collaboration with HSCI’s Clifford Woolf and Brian Wainger, Eggan studied the functional properties of motor neurons affected by ALS and discovered that an FDA-approved anti-epileptic drug, retigabine, lessened the impact of the disease in the cells. A Phase II clinical trial will test the effects of the drug in ALS patients.